Looking at the phase 2 results that came out last year it seems very promising:
Oral Muvalaplin for Lowering of Lipoprotein(a): A Randomized Clinical Trial - PubMed
Muvalaplin resulted in placebo-adjusted reductions in lipoprotein(a) of 47.6% (95% CI, 35.1%-57.7%), 81.7% (95% CI, 78.1%-84.6%), and 85.8% (95% CI, 83.1%-88.0%) for the 10-mg/d, 60-mg/d, and 240-mg/d dosages, respectively, using an intact lipoprotein(a) assay and 40.4% (95% CI, 28.3%-50.5%), 70.0% (95% CI, 65.0%-74.2%), and 68.9% (95% CI, 63.8%-73.3%) using an apolipoprotein(a)-based assay. Dose-dependent reductions in apolipoprotein B were observed at 8.9% (95% CI, -2.2% to 18.8%), 13.1% (95% CI, 4.4%-20.9%), and 16.1% (95% CI, 7.8%-23.7%) at 10 mg/d, 60 mg/d, and 240 mg/d, respectively
Even if reducing lp(a) somehow doesn’t actually reduce the rate of heart attacks, it seems it’s reducing Apob at similar rates to mono-dosing Ezetimibe or Bempedoic Acid which should be enough to move the needle on its own. On top of that this is an oral drug which makes it even more attractive. The phase 3 trial has already started but I believe it’s running until 2031.I would be willing to take it on the results of the phase 2 trials alone to be honest. The sooner we can get our hands on this the better.